Embla Medical hf. (OSSUY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Embla Medical hf. (OSSUY) trades at $4.13 with AI Score 47/100 (Grade C). Embla Medical hf. specializes in the design, development, manufacture, and sale of non-invasive orthopedic products. Market cap: $1.76B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for OSSUY: OSSUY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OSSUY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OSSUY: the 1 perspectives are evenly split.
How is this calculated? →Embla Medical hf. (OSSUY) Healthcare & Pipeline Overview
Embla Medical hf., a global orthopedics company founded in 1971, focuses on non-invasive orthopedic products with a market capitalization of $1.76B. Operating across the Americas, EMEA, and Asia-Pacific, Embla maintains a 9.0% profit margin and a 58.2% gross margin, positioning it as a key player in the medical devices sector.
What Is the Investment Thesis for OSSUY?
Embla Medical hf. presents a compelling investment case based on its established market position, consistent profitability, and focus on non-invasive orthopedic solutions. With a market capitalization of $1.76B and a P/E ratio of 18.83, the company demonstrates financial stability and growth potential. A profit margin of 9.0% and a gross margin of 58.2% indicate efficient operations and strong pricing power. Key growth catalysts include expansion into new geographic markets and the introduction of innovative product lines. However, potential risks include increasing competition in the orthopedics market and regulatory changes in the healthcare industry. The company's low beta of 0.43 suggests relatively low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
OSSUY Key Highlights
- Market capitalization of $1.76B indicates a strong market presence.
- P/E ratio of 18.83 reflects investor confidence in future earnings.
- Profit margin of 9.0% demonstrates efficient operations.
- Gross margin of 58.2% indicates strong pricing power and cost management.
- Beta of 0.43 suggests relatively low volatility compared to the market.
Who Are OSSUY's Competitors?
OSSUY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALFRY Alfresa Holdings Corporation | $13.80 | +0.00% | $2.51B | 49 |
| DMPHF Dermapharm Holding SE | $53.00 | +0.00% | $2.63B | 50 |
| GGNDF GN Store Nord A/S | $14.35 | +7.17% | $2.09B | 41 |
| GNNDY GN Store Nord A/S | $41.25 | -0.10% | $2.00B | 44 |
| HBMHF HBM Holdings Limited | $2.52 | +61.54% | $2.10B | 53 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OSSUY's Key Strengths?
- Global presence and established distribution network.
- Focus on non-invasive orthopedic solutions.
- Strong brand reputation in the orthopedics market.
- Commitment to innovation and product development.
What Are OSSUY's Weaknesses?
- Dependence on distributors for sales and marketing.
- Limited presence in emerging markets compared to larger competitors.
- Potential for product recalls or liability claims.
- Exposure to currency fluctuations.
What Could Drive OSSUY Stock Higher?
- Launch of new non-invasive orthopedic products in Q3 2026.
- Expansion into emerging markets in Asia-Pacific and Latin America.
- Integration of digital health technologies into orthopedic solutions.
- Strategic acquisitions of complementary businesses in 2027.
- Increased demand for non-invasive orthopedic solutions due to aging population.
What Are the Key Risks for OSSUY?
- Increasing competition from larger medical device companies.
- Regulatory changes in the healthcare industry.
- Economic downturns that reduce healthcare spending.
- Product recalls or liability claims.
- Exposure to currency fluctuations.
What Are the Growth Opportunities for OSSUY?
- Expansion into Emerging Markets: Embla Medical hf. has the opportunity to expand its presence in emerging markets, particularly in Asia-Pacific and Latin America. These regions are experiencing rapid growth in healthcare spending and increasing demand for advanced orthopedic solutions. By establishing strategic partnerships and distribution networks, Embla Medical can tap into these high-growth markets and increase its revenue streams. The market size for orthopedic devices in emerging markets is projected to reach $15 billion by 2028, presenting a significant growth opportunity for the company.
- Development of Innovative Products: Embla Medical hf. can drive growth by investing in the development of innovative orthopedic products that address unmet clinical needs. This includes developing new materials, designs, and technologies that improve the performance and durability of orthopedic implants and devices. By collaborating with leading researchers and clinicians, Embla Medical can stay at the forefront of innovation and gain a competitive edge in the market. The global market for innovative orthopedic products is estimated to be worth $10 billion by 2027.
- Strategic Acquisitions: Embla Medical hf. can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. By acquiring companies with complementary products or technologies, Embla Medical can strengthen its market position and accelerate its growth. Potential acquisition targets include companies specializing in sports medicine, joint reconstruction, and spine surgery. The company could also acquire companies with strong distribution networks in key geographic markets. The timeline for potential acquisitions is within the next 3-5 years.
- Focus on Personalized Medicine: Embla Medical hf. can leverage advances in personalized medicine to develop customized orthopedic solutions that are tailored to the individual needs of patients. This includes using genetic information, imaging data, and other patient-specific factors to design implants and devices that optimize outcomes. By offering personalized solutions, Embla Medical can differentiate itself from competitors and attract patients seeking the most advanced and effective treatments. The market for personalized orthopedic solutions is expected to grow rapidly in the coming years, driven by increasing awareness of the benefits of personalized medicine.
- Enhance Digital Health Solutions: Embla Medical hf. can integrate digital health technologies into its orthopedic products and services to improve patient engagement, monitoring, and rehabilitation. This includes developing mobile apps, wearable sensors, and telehealth platforms that allow patients to track their progress, communicate with their healthcare providers, and receive remote support. By offering digital health solutions, Embla Medical can enhance the patient experience and improve outcomes. The market for digital health solutions in orthopedics is projected to reach $5 billion by 2029.
What Opportunities Does OSSUY Have?
- Expansion into new geographic markets.
- Development of innovative orthopedic products.
- Strategic acquisitions of complementary businesses.
- Integration of digital health technologies into orthopedic solutions.
What Threats Does OSSUY Face?
- Increasing competition from larger medical device companies.
- Regulatory changes in the healthcare industry.
- Economic downturns that reduce healthcare spending.
- Technological obsolescence.
What Are OSSUY's Competitive Advantages?
- Established brand reputation in the orthopedics market.
- Strong distribution network across multiple geographic regions.
- Focus on non-invasive orthopedic solutions.
- Commitment to innovation and product development.
What Does OSSUY Do?
Founded in 1971 by Össur Kristinsson, Embla Medical hf. has evolved into a global orthopedics company specializing in the design, development, manufacture, and sale of non-invasive orthopedic products. Headquartered in Reykjavík, Iceland, Embla Medical operates across three primary geographical segments: the Americas, Europe Middle-East and Africa (EMEA), and Asia-Pacific. The company's product portfolio includes a range of orthopedic solutions aimed at improving mobility and quality of life for patients. Embla Medical's commitment to innovation and quality has enabled it to establish a strong presence in the global orthopedics market. With approximately 4,000 employees, the company continues to focus on expanding its product offerings and geographic reach. Embla Medical's products are utilized by healthcare professionals and patients worldwide, addressing various orthopedic conditions. The company's strategic focus on non-invasive solutions aligns with the growing demand for less invasive treatment options in the healthcare industry. Embla Medical's market capitalization stands at $1.57 billion, reflecting its significant position in the orthopedics sector.
What Products and Services Does OSSUY Offer?
- Designs and develops non-invasive orthopedic products.
- Manufactures a range of orthopedic implants and devices.
- Sells its products globally through a network of distributors and sales representatives.
- Focuses on improving mobility and quality of life for patients with orthopedic conditions.
- Operates in the Americas, Europe Middle-East and Africa, and Asia-Pacific regions.
- Offers solutions for joint reconstruction, sports medicine, and trauma care.
- Invests in research and development to innovate new orthopedic technologies.
How Does OSSUY Make Money?
- Develops and manufactures orthopedic products.
- Sells products through distributors and direct sales.
- Generates revenue from product sales in various geographic regions.
- Reinvests in R&D to create new products and technologies.
What Industry Does OSSUY Operate In?
Embla Medical hf. operates within the global orthopedics market, which is characterized by increasing demand for non-invasive and minimally invasive solutions. The market is driven by an aging population, rising incidence of orthopedic conditions, and technological advancements in medical devices. Key competitors include ALFRY, DMPHF, GGNDF, GNNDY and HBMHF. Embla Medical's focus on non-invasive orthopedic products positions it favorably within this growing market, allowing it to capitalize on the trend towards less invasive treatment options. The company's global presence and established distribution network further enhance its competitive advantage.
Who Are OSSUY's Key Customers?
- Hospitals and orthopedic clinics.
- Surgeons and other healthcare professionals.
- Patients with orthopedic conditions.
- Rehabilitation centers.
FY2026 estForward Outlook
Wall Street analysts project Embla Medical hf. revenue of about $1.02B for fiscal 2026, with EPS near $0.00. The estimate reflects 5 contributing analysts.
ROE 10%Key Financial Metrics
Return on equity for Embla Medical hf. stands at 9.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.0%, showing how much profit it generates from its asset base. OSSUY trades at a trailing price-to-earnings ratio of 18.93, below the Healthcare sector average of ~23x. Its free cash flow yield is 6.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.21 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 8/9Financial Health
Embla Medical hf.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.77 places it in the grey zone, a middle ground that warrants monitoring.
OSSUY Valuation & Market Position
With a $1.76B market cap, Embla Medical hf. sits in the small-cap segment of the market. Relative to its peer group, OSSUY's quantitative score of 47/100 is roughly in line with the peer average of 47/100.
OSSUY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Global presence and established distribution network.
- Focus on non-invasive orthopedic solutions.
- Strong brand reputation in the orthopedics market.
- Commitment to innovation and product development.
Bear Case
- Dependence on distributors for sales and marketing.
- Limited presence in emerging markets compared to larger competitors.
- Potential for product recalls or liability claims.
- Exposure to currency fluctuations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
OSSUY Latest News
No recent news available for OSSUY.
OSSUY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OSSUY.
Price Targets
Wall Street price target analysis for OSSUY.
OSSUY MoonshotScore
What does this score mean?
The MoonshotScore rates OSSUY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sveinn Solvason
CEO
Sveinn Solvason is the CEO of Embla Medical hf., leading a workforce of 4,000 employees. His background includes extensive experience in the healthcare industry, with a focus on medical devices and orthopedic solutions. Prior to joining Embla Medical, Sveinn held leadership positions at several multinational healthcare companies, where he was responsible for driving growth and innovation. He holds an MBA from a leading business school and a degree in biomedical engineering.
Track Record: Under Sveinn Solvason's leadership, Embla Medical hf. has expanded its global presence and launched several innovative orthopedic products. He has focused on strengthening the company's distribution network and investing in research and development. Key milestones during his tenure include the acquisition of a complementary business and the successful integration of digital health technologies into Embla Medical's product offerings.
OSSUY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Embla Medical hf. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no reporting requirements, which increases the risk for investors. Trading on the OTC Other tier differs significantly from trading on major exchanges like the NYSE or NASDAQ, where companies must adhere to strict listing standards and reporting requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial reporting requirements.
- Low liquidity and wide bid-ask spreads.
- Increased risk of price manipulation.
- Lack of regulatory oversight.
- Potential for delisting or suspension of trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Check for any legal or regulatory issues.
- Monitor trading volume and price movements.
- Consult with a financial advisor.
- Established history of operations.
- Presence of a reputable management team.
- Positive reviews or testimonials from customers.
- Patents or other intellectual property.
- Partnerships with established companies.
What Investors Ask About Embla Medical hf. (OSSUY) — Healthcare
What does Embla Medical hf. do?
Embla Medical hf. is a global orthopedics company specializing in the design, development, manufacture, and sale of non-invasive orthopedic products. The company operates across the Americas, Europe Middle-East and Africa, and Asia-Pacific regions. Its product portfolio includes a range of orthopedic solutions aimed at improving mobility and quality of life for patients. Embla Medical focuses on providing less invasive treatment options in the healthcare industry, addressing various orthopedic conditions through its innovative products and established distribution network.
What are the main risks for OSSUY?
Embla Medical hf. faces several potential risks, including increasing competition from larger medical device companies, regulatory changes in the healthcare industry, and economic downturns that could reduce healthcare spending. The company is also exposed to currency fluctuations and potential product recalls or liability claims. Additionally, as an OTC-listed company, OSSUY carries risks associated with lower liquidity, limited disclosure, and potential price volatility. Investors should carefully consider these risks before investing in OSSUY.
What are the key factors to evaluate for OSSUY?
Embla Medical hf. (OSSUY) holds an AI score of 47/100 (low). Not financial advice.
How frequently does OSSUY data refresh on this page?
OSSUY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OSSUY's recent stock price performance?
Embla Medical hf. (OSSUY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global presence and established distribution network. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OSSUY overvalued or undervalued right now?
Valuing Embla Medical hf. (OSSUY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OSSUY?
Before investing in Embla Medical hf. (OSSUY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OSSUY to a portfolio?
Key strength of Embla Medical hf. (OSSUY): Global presence and established distribution network. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- OTC analysis is based on general information about the OTC market and may not be specific to OSSUY.
- AI analysis is pending and may provide additional insights.